⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11826120 | 0.76 | PDE7A (0.43) | — | |
| SCHEMBL27851500 | 0.75 | TDP1 (0.50) | — | |
| SCHEMBL872076 | 0.74 | PDE7A (0.46) | — | |
| SCHEMBL28906801 | 0.73 | ALDH1A1 (0.56) | — | |
| SCHEMBL9375139 | 0.73 | — | — | |
| SCHEMBL4648229 | 0.73 | — | — | |
| SCHEMBL10933026 | 0.73 | — | — | |
| SCHEMBL11559302 | 0.73 | — | — | |
| SCHEMBL5841002 | 0.73 | — | — | |
| SCHEMBL1306343 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575974-B1 | MODIFIED GUANOSINES HAVING FLAVOURING ACTIVITY | FRUCTAMINE SPA (IT) | 2008-03-19 | — | — | EP | claimed |
| EP-2593139-B1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170232017-A1 | TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016014390-A1 | COMPOSITIONS AND METHODS FOR MEK INHIBITOR COMBINATION THERAPY IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015171647-A1 | TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150005263-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005262-A1 | HYPOXIA ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20140072624-A1 | UNIT DOSE FORM FOR ORAL ADMINISTRATION | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130296273-A1 | TREATMENT OF BLOOD CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| WO-2011050160-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2008022467-A1 | 2-SUBSTITUTED AZAIN DOLES AND 2 SUBSTITUTED THIENOPYRROLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2008-02-28 | — | — | WO | disclosed |